2021
DOI: 10.1002/oby.23146
|View full text |Cite|
|
Sign up to set email alerts
|

Pharmacotherapies for Post‐Bariatric Weight Regain: Real‐World Comparative Outcomes

Abstract: Objective This study aimed to compare outcomes of treatment strategies for weight regain after bariatric surgery. Methods This is a retrospective analysis of 207 individuals treated for post‐bariatric weight regain at an academic center from January 1, 2014, through November 25, 2019. Percentage body weight loss was compared after 3, 6, 9, and 12 months of treatment among an intensive lifestyle modification (ILM) group, a non–glucagon‐like‐1 receptor agonist (GLP‐1‐RA)‐based weight‐loss pharmacotherapy (WLP) g… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
23
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 41 publications
(26 citation statements)
references
References 28 publications
3
23
0
Order By: Relevance
“…There is limited data about the use of GLP-1 RA in postbariatric WR or IWL, which were found to be more effective for treating post-bariatric weight regain than non-GLP-1 RA-based pharmacotherapies regardless of surgery type [21]. According to a retrospective review comparing amphetamine-derived phentermine with phentermine-topiramate, phentermine and phentermine-topiramate in addition to diet and exercise in post-RYGB and LAGB patients induced weight loss of 6.35 kg (12.8% excess weight loss) and 3.81 kg (12.9% EWL) within 90 days, respectively [14].…”
Section: Discussionmentioning
confidence: 99%
“…There is limited data about the use of GLP-1 RA in postbariatric WR or IWL, which were found to be more effective for treating post-bariatric weight regain than non-GLP-1 RA-based pharmacotherapies regardless of surgery type [21]. According to a retrospective review comparing amphetamine-derived phentermine with phentermine-topiramate, phentermine and phentermine-topiramate in addition to diet and exercise in post-RYGB and LAGB patients induced weight loss of 6.35 kg (12.8% excess weight loss) and 3.81 kg (12.9% EWL) within 90 days, respectively [14].…”
Section: Discussionmentioning
confidence: 99%
“…Scientific research confirms that a constructive relationship between a doctor and a patient favors, among others: recovery, compliance with recommendations, and reduced the risk of relapse [48]. The nature of the therapeutic relationship is determined by many components, including the patient's attitude but also the attitude of the doctor.…”
Section: Doctor-patient Relationshipmentioning
confidence: 97%
“…There are no studies evaluating the individual efficacies of naltrexone, bupropion, or naltrexone/bupropion specifically in the post-bariatric surgery population. A few studies have investigated the effectiveness of obesity pharmacotherapy in general, in which monotherapies naltrexone or bupropion and combination naltrexone/bupropion were minimally represented ( 17 , 29 , 30 ). The strongest body of evidence for weight loss efficacy stems from phase 3 randomized controlled trials of combination naltrexone/bupropion, from which individuals with a history of bariatric surgery were excluded, but demonstrated about 5% placebo-subtracted weight loss at one year ( 31 , 32 ).…”
Section: Pharmacologic Management For Post-bariatric Surgery Weight O...mentioning
confidence: 99%